PGDx elio tissue complete enables you to confidently advise your oncologists and gain new research advantages with our sample-to-answer IVD kit that includes fully automated bioinformatics and dedicated customer support.
A pan solid tumor CGP test
Benefits of the PGDx pan solid tumor CGP test
PGDx elio tissue complete enables you to confidently advise your oncologists and gain new research advantages with our sample-to-answer IVD kit that includes fully automated bioinformatics and dedicated customer support.
Enhance your lab capabilities
Offer rapid, scalable genomic testing in your lab, backed by our proprietary bioinformatics, and retain complete control over valuable patient samples and data
Guide optimal treatment plans
Confidently advise your oncologists with reliable and actionable genomic insights that facilitate the best treatment decisions
Enable new opportunities
Activate new research opportunities and unlock new potential paths to reimbursement
Cleared
Gene panel
Day sample-to-result turnaround time
Solid tumor types
Weeks to go live
People covered for Medicare reimbursement
PGDx elio bioinformatics rapidly and accurately identifies cancer mutations, empowering every lab to provide timely and trustworthy results. High quality training data, expert curation and machine learning algorithms combine to provide best-in-class identification of cancer mutations.
PGDx elio tissue complete makes precision oncology available in-house so you can quickly access comprehensive tumor insights. That empowers you to make timely treatment decisions that optimize outcomes.
In-house support
Keeping cases within your trusted local team lets you leverage your local pathologist expertise for questions and clarifications
Guide confident treatment decisions
FDA cleared CGP test provides accurate and clinically significant insights from actionable biomarkers
Timely care planning
Easily-integrated, easy-to-interpret reporting that includes a wide array of actionable biomarkers helps guide and expedite your treatment decisions
Cleared
Gene panel
Day sample-to-result turnaround time
Solid tumor types
Weeks to go live
People covered for Medicare reimbursement
PGDx elio bioinformatics rapidly and accurately identifies cancer mutations, empowering every lab to provide timely and trustworthy results. High quality training data, expert curation and machine learning algorithms combine to provide best-in-class identification of cancer mutations.
PGDx elio tissue complete is the only FDA cleared comprehensive genomic profiling kit on the market, eliminating the need for time-consuming and costly validation. Standardized, distributed kits enable global access to patient cohorts relevant for your clinical trials.
Proven performance
Our FDA cleared CGP kit highlights clinically reportable biomarkers and genomic signatures, powered by a bioinformatics pipeline that leverages machine learning, validated against 400M+ base pairs
Global market access & availability
A growing network of global lab partnerships supports local access to patient cohorts relevant for your clinical trials via our distributed testing model and regulatory compliance across multiple geographies
Stable platform offering reduced risk
Our deep expertise, validated by decades of publications, key opinion leader engagement and knowledgeable white glove support ensures we can meet your needs from set-up to launch and beyond
Cleared
Gene panel
Day sample-to-result turnaround time
Solid tumor types
Weeks to go live
People covered for Medicare reimbursement
PGDx elio bioinformatics rapidly and accurately identifies cancer mutations, empowering every lab to provide timely and trustworthy results. High quality training data, expert curation and machine learning algorithms combine to provide best-in-class identification of cancer mutations.
Researchers all around the world are using PGDx elio tissue complete. Here are some of the breakthroughs that have been made possible.
Derazantinib and Atezolizumab in Patients With Urothelial Cancer (FIDES-02).
Derazantinib Alone or in Combination With Paclitaxel, Ramucirumab or Atezolizumab in Gastric Adenocarcinoma (FIDES-03).
A Study of Biomarker-Directed, Pembrolizumab (MK-3475) Based Combination Therapy for Advanced Non-Small Cell Lung Cancer (MK-3475 – 495/KEYNOTE-495).
Prevention of recurrent disease by additional chemotherapy in patients with detectable circulating tumor DNA in the blood after surgery for stage II (lymph nodes unaffected) colon cancer.
This test identifies somatic mutations with high accuracy and sensitivity, providing information on single nucleotide variants (SNVs), insertions/deletions (indels), amplifications, translocations, microsatellite instability (MSI) status and tumor mutation burden (TMB) for use by qualified professionals to guide treatment decisions.
Patent Disclaimer
For In Vitro Diagnostic Use.
©2023 Personal Genome Diagnostics Inc. All Rights Reserved.